What does the March 03, 2026 SRPT analyst rating from Jefferies mean?

Jefferies' maintained Buy on March 03, 2026 signals continued confidence in Sarepta's recovery prospects. The SRPT analyst rating indicates support, not a new catalyst, and the note lacked a fresh price target. Investors should weigh clinical and commercial risks.

Did Jefferies set a new SRPT price target with the maintained Buy?

No. The Jefferies note on March 03, 2026 reiterated a Buy but did not publish a new SRPT price target in the public summary. Traders should monitor company guidance and future analyst updates for price target changes.

How should investors use the SRPT analyst rating alongside Meyka's grade?

Combine the SRPT analyst rating with Meyka AI rates SRPT with a grade of B to get broader context. Use both signals with revenue guidance, trial milestones, and risk appetite before making investment decisions.

How did the market react to the Jefferies note on SRPT?

The market moved modestly after the note, with a **-1.76% (-$0.29)** change noted in the summary. That reaction suggests the reiteration was priced as confirmation rather than surprise.

Analyst Ratings

Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026

ByDanny Kontos March 4, 2026March 4, 2026

Jefferies on March 03, 2026 maintained a Buy on Sarepta Therapeutics, Inc. (SRPT), calling the stock a potential “recovery story”. The SRPT analyst rating note arrived after recent company commentary and reflects conviction in pipeline progress and commercial execution. The update shows no rating flip, but investors should note the stock moved -1.76% (-$0.29) around the report.